

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

January 28, 2022

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers,
Dalal Street, Mumbai-400001
Script Id: 506365

Subject: Outcome of Board Meeting Held on Friday, January 28, 2022

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. January 28, 2022, have discussed the following matters:

1. Approval of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021 along with the Limited Review Report thereon.
2. Appointment of M/s. Kavita Khatri & Associates as an Secretarial Auditor for the Financial Year 2021-2022.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI
DIRECTOR
(DIN - 03063364)



Sanjay Rane & Associates

CHARTERED ACCOUNTANTS

C-403, Marathon Next Gen. Innova,
Opp. Peninsula Corporate Park,
Off Ganpatrao Kadam Marg,
Lower Parel, Mumbai-400 013.

Phone : 49198585
Telefax : 49198521
Email : admin@ssrane.net
Website : www.ssraneandco.com

LIMITED REVIEW REPORT

To,

Board of Directors of Chemo Pharma Laboratories Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of **CHEMO PHARMA LABORATORIES LIMITED** for the quarter ended December 31, 2021 and year to date results for the nine months period from April 01, 2021 to December 31, 2021 ("**the Statement**").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("**Ind AS 34**"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("**Listing Regulations**"). Our responsibility is to issue a report on the statement based on our review.


We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates

Chartered Accountants

Firm Reg. No. 121089W



CA. Abhijeet Deshmukh

Partner

Membership No. 129145



Date: January 19, 2022

UDIN: 22129145AAAABM8983

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER 2021

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Nine Months Ended		Year Ended
		31st Dec. 2021	30th Sept. 2021	31st Dec. 2020	31st Dec. 2021	31st Dec. 2020	31st March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	-	-	-	-	-	-
II	Other Income	3,613	1,896	1,116	6,601	4,106	6,680
III	Total Revenue (I + II)	3,613	1,896	1,116	6,601	4,106	6,680
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	542	365	434	1,259	896	1,262
	(5) Depreciation and Amortisation Expenses	50	91	-	140	-	239
	(6) Administrative and Other Expenses	230	321	233	981	907	2,071
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	822	777	667	2,380	1,803	3,572
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	2,791	1,119	449	4,221	2,303	3,108
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	2,791	1,119	449	4,221	2,303	3,108
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	2,791	1,119	449	4,221	2,303	3,108
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	503
	(2) Tax Adjustment Previous Year	-	-	-	-	-	104
	(3) Deffered Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	2,791	1,119	449	4,221	2,303	2,501
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	2,791	1,119	449	4,221	2,303	2,501
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	2,791	1,119	449	4,221	2,303	2,501
XVIII	Earnings per Share :						
	(1) Basic	1.86	0.75	0.30	2.81	1.54	1.67
	(2) Diluted						

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2021 have been reviewed by the Audit Committee in their Meeting held on 28.01.2022 and approved by the Board of Directors of its Meeting held on 28.01.2022. The Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo Pharma Laboratories Limited

Ashok Somani

Ashok Somani

Director

DIN : 03063364



Date : 28th January, 2022

Place : Mumbai

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K


Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2021

(Rupees in Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			NINE MONTHS ENDED		AUDITED YEAR ENDED
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)						
Benefit / (Charge):						
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-	-	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
Net Profit / (Loss) for the Period (as per AS)	2,791	1,119	449	4,221	2,303	2,501

For Chemo Pharma Laboratories Limited



Ashok Somani
Director
DIN : 03063364

Date: 28th January, 2022
Place: Mumbai

